Clinical Trial Update: Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for tandutinib in recurrent or progressive glioblastoma (Phase 1/2) reports completion with results posted in 2017. The study included gli…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Giant Cell Glioblastoma
• Glioblastoma
• Gliosarcoma

Drugs mentioned

• Tandutinib (tandutinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Brain Tumor, Adult Giant Cell Glioblastoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-04-07